Showing results (1-10 of 22) with videos related to
Sort By:
Pageof 3
Oncology (Williston Park, N.Y.)|October 17, 2002
Anemia in cancer patients: significance, epidemiology, and current therapyN Simon TchekmedyianOncology (Williston Park, N.Y.)|October 17, 2002
Practitioners' practical model for managing cancer-related anemiaRobert E Smith, Simon TchekmedyianOncology (Williston Park, N.Y.)|November 19, 2002
Darbepoetin alfa administered every 2 weeks alleviates anemia in cancer patients receiving chemotherapyJohn A Glaspy, N Simon TchekmedyianCancer Investigation|July 2, 2010
Disease progression increases the risk of skeletal-related events in patients with bone metastases from castration-resistant prostate cancer, lung cancer, or other solid tumorsN Simon Tchekmedyian, Yin-Miao Chen, Fred SaadClinical Drug Investigation|December 14, 2006
Resource utilisation and time commitment associated with correction of anaemia in cancer patients using epoetin alfaKenneth R Meehan, N Simon Tchekmedyian, Robert E Smith, et al.Cancer|July 2, 2003
The relationship between psychologic distress and cancer-related fatigueN Simon Tchekmedyian, Joel Kallich, Anne McDermott, et al.Clinical Lung Cancer|November 24, 2004
Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complicationsVera Hirsh, N Simon Tchekmedyian, Lee S Rosen, et al.The Oncologist|February 14, 2007
Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapyDavid H Henry, Naomi V Dahl, Michael Auerbach, et al.The Journal of Urology|May 29, 2003
Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancerMatthew R Smith, James Eastham, Donald M Gleason, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2007
A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancerEric J Small, N Simon Tchekmedyian, Brian I Rini, et al.Pageof 3